实用肝脏病杂志 ›› 2020, Vol. 23 ›› Issue (6): 893-896.doi: 10.3969/j.issn.1672-5069.2020.06.034

• 肝癌 • 上一篇    下一篇

胆道支架置入术联合125I粒子条胆道腔内照射治疗恶性梗阻性黄疸患者临床研究

包凯沪, 顾建平   

  1. 210006 南京市 南京医科大学附属南京医院介入血管科
  • 收稿日期:2020-02-21 发布日期:2021-02-25
  • 通讯作者: 顾建平,E-mail:cjr.gujianping@vip.163.com
  • 作者简介:包凯沪,男,33岁,硕士研究生,主治医师。主要从事介入诊疗研究。E-mail:bking718@163.com

Effects of 125I seed implantation at base of biliary stenting in the treatment of patients with malignant obstructive jaundice

Bao Kaihu, Gu Jianping   

  1. Interventional Department of Vascular Diseases, Nanjing Hospital Affiliated to Nanjing Medical University, Nanjing 210006, Jiangsu Province, China
  • Received:2020-02-21 Published:2021-02-25

摘要: 目的 探讨胆道支架置入联合125 I 粒子条胆道内照射治疗恶性梗阻性黄疸(MOJ)患者的临床疗效。方法 2015年6月~2017年10月我院收治的96例MOJ患者,55例行经皮经肝胆管引流( PTCD) 后行胆道支架植入术治疗(对照组),41例接受PTCD术后行胆道支架植入术联合125 I 粒子条胆道腔内照射治疗(观察组)。结果 96例患者手术均获得成功,术后两组患者均无明显出血、腹膜炎、胆道穿孔、肠炎、胆道感染、白细胞明显降低、恶心、呕吐等并发症发生;在术后1个月,观察组和对照组血清TBIL分别为(32.6±19.2)μmol/L对(107.8±20.2)μmol/L,血清DBIL分别为(23.4± 12.4)μmol/L对(97.4±12.5)μmol/L,血清ALT分别为(30.4±16.5)U/L对(85.9±19.8)U/L,血清AST分别为(30.7±13.2)U/L对(71.4±18.9)U/L,血清CA199分别为(30.7±13.2)U/L对(71.4±18.9)U/L,差异均具有统计学意义(P<0.05);术后,观察组胆道通畅时间为(6.4±3.8)个月,显著长于对照组【(2.9±1.8)月,P<0.05】;观察组总有效率为53.7%,显著高于对照组的30.9%(P<0.05);观察组患者中位生存时间为10.7 个月,显著长于对照组患者的6.2 个月(P<0. 05) 。结论 采取胆道支架联合胆道腔内125 I 粒子条植入照射治疗恶性梗阻性黄疸患者能抑制肿瘤生长,延长支架开放时间,延长患者生存时间,适合姑息性治疗。

关键词: 恶性梗阻性黄疸, 经皮经肝胆管引流, 胆道支架, 125 I 粒子, 治疗

Abstract: Objective To investigate the clinical effects of 125I seed implantation at base of biliary stenting for the treatment of patients with malignant obstructive jaundice(MOJ). Methods 96 MOJ patients were admitted to our hospital from June 2015 to October 2017, and 55 patients out of them in the control group underwent percutaneous transhepatic bile duct drainage (PTCD) followed by biliary stent implantation and 45 patients in the observation group underwent PTCD followed by biliary stent implantation and 125I particle implantation. The liver function indexes,including total bilirubin (TBIL), serum alanine aminotransferase (ALT), and serum aspartate aminotransferase (AST) ] and serum tumor marker CA199 levels before and 1 month after operation, the recent clinical efficacy, survival and postoperative complications in the two groups were compared. Results The interventional operation in the 96 patients was all successful; there were no obvious bleeding, peritonitis, biliary tract perforation, enteritis, biliary tract infection, reduction of white blood cell counts, nausea, vomiting and other complications in the two groups after operation; one month after surgery, serum bilirubin levels in the observation group and in the control group were (32.6±19.2) μmol / Lvs. (107.8±20.2) μmol / L, serum direct bilirubin levels were (23.4±12.4) μmol / L vs (97.4±12.5) μmol / L, serum ALT levels were (30.4±16.5)U/L vs. (85.9±19.8)U/L, serum AST levels were (30.7±13.2)U/L vs. (71.4±18.9)U/L, and serum CA199 levels were (30.7±13.2)U/L vs. (71.4±18.9)U/L, with significant differences between the two groups (all P <0.05); the average postoperative biliary patency in the observation group was (6.4±3.8) months, which was significantly longer than that in the control group [(2.9±1.8) months, P <0.05]; the total effective rate in the observation group was 53.7%, which was significantly higher than that in the control group (30.9%, P <0.05); the median survival time in the observation group was 10.7 months, which was significantly longer than that in the control group (6.2 months, P<0.05). Conclusion The combination of biliary stent and 125I seed implantation is an alternative option for patients with MOJ, with the subsidence of jaundice, inhibition of tumor growth, which might prolong the survival time of patients.

Key words: Malignant obstructive jaundice, Percutaneous transhepatic cholangial drainage, Biliary stent, 125I seed implantation, Therapy